Waiting time for kidney transplantation based on calculated panel reactive antibodies: experience of a southern Brazilian center.

Autor:	Ramos LA; Universidade de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil., Schiavo T; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Montagner J; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Bundcher C; Universidade de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil., Kist R; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Garcia VD; Universidade de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Neumann J; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil., Keitel E; Universidade de Ciências da Saúde de Porto Alegre, Porto Alegre, RS, Brazil.; Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, RS, Brazil.
Jazyk:	English; Portuguese
Zdroj:	Jornal brasileiro de nefrologia [J Bras Nefrol] 2024 Jan-Mar; Vol. 46 (1), pp. 79-84.
DOI:	10.1590/2175-8239-JBN-2022-0132en
Abstrakt:	Introduction: The aim of this study was to analyze the waiting list for kidney transplantation in our hospital according to candidate's panel reactive antibodies (cPRA) and its outcomes. Methods: One thousand six hundred forty patients who were on the waiting list between 2015 and 2019 were included. For the analysis, hazard ratios (HR) for transplant were estimated by Fine and Gray's regression model according to panel reactivity and HR for graft loss and death after transplantation. Results: The mean age was 45.39 ± 18.22 years. Male gender was predominant (61.2%), but the proportion decreased linearly with the increase in cPRA (p < 0.001). The distribution of patients according to panels were: 0% (n = 390), 1% - 49% (n = 517), 50% - 84% (n = 269), and ≥ 85% (n = 226). Transplantation was achieved in 85.5% of the sample within a median time of 8 months (CI 95%: 6.9 - 9.1). The estimated HRs for transplantation during the follow-up were 2.84 (95% CI: 2.51 - 3.34), 2.41(95%CI: 2.07 - 2.80), and 2.45(95%CI: 2.08 - 2.90) in the cPRA range of 0%, 1%-49%, and 50%-84%, respectively, compared to cPRA ≥ 85 (p < 0.001). After transplantation, the HR for graft loss was similar in the different cPRA groups, but the HR for death (0.46 95% CI 0.24-0.89 p = 0.022) was lower in the 0% cPRA group when adjusted for age, gender, and presence of donor specific antibodies (DSA). Conclusion: Patients with cPRA below 85% are more than twice as likely to receive a kidney transplantation with a shorter waiting time. The risk of graft loss after transplantation was similar in the different cPRA groups, and the adjusted risk of death was lower in nonsensitized recipients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu